keyword
https://read.qxmd.com/read/38618735/assessing-the-5-year-persistence-in-positive-clinical-response-with-innovative-psoriasis-treatments-a-network-meta-analysis-of-pasi-score
#1
JOURNAL ARTICLE
Husein Husein-ElAhmed, Sara Husein-ElAhmed
BACKGROUND: Psoriasis is a chronic skin condition, for which the approval of several biologics has made a dramatic impact. Despite their initial treatment effectiveness, the challenge lies in understanding the long-term responses, as they may diminish over time. Limitations of the drug survival analysis warrant the application of additional outcomes to fully capture the performance of a biologic. We aimed to provide a broader perspective on the global landscape of biologic agents' persistence in positive clinical response by comparing innovative therapies over a 5-year period through a systematic review and network meta-analysis (NMA)...
April 15, 2024: Clinical and Experimental Dermatology
https://read.qxmd.com/read/38605947/deciphering-the-causal-association-and-co-disease-mechanisms-between-psoriasis-and-breast-cancer
#2
JOURNAL ARTICLE
Xujia Li, Lingli Huang, Yue Yan, Yuming Rong, Xuxian Chen, Mengge Gao, Jinsheng Huang
BACKGROUND: Prior research has indicated a link between psoriasis and the susceptibility to breast cancer (BC); however, a definitive causal relationship remains elusive. This study sought to elucidate the causal connection and shared underlying mechanisms between psoriasis and BC through bidirectional Mendelian randomization (MR) and bioinformatic approaches. METHODS: We employed a bidirectional MR approach to examine the potential causal connection between psoriasis and BC...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38599660/defining-d-iraes-consensus-based-disease-definitions-for-the-diagnosis-of-dermatologic-adverse-events-from-immune-checkpoint-inhibitor-therapy
#3
JOURNAL ARTICLE
Steven T Chen, Yevgeniy R Semenov, Allireza Alloo, Daniel Q Bach, Allison Betof Warner, Amina Bougrine, Leeann Burton, Laura C Cappelli, Mariana Castells, Justine Cohen, Anna K Dewan, Riley Fadden, Lauren Guggina, Aparna Hegde, Victor Huang, Douglas B Johnson, Benjamin Kaffenberger, Daniela Kroshinsky, Shawn Kwatra, Bernice Kwong, Mario E Lacouture, Cecilia Larocca, Jonathan Leventhal, Alina Markova, Jon McDunn, Meghan J Mooradian, Jarushka Naidoo, Jennifer Choi, Vinod Nambudiri, Caroline A Nelson, Anisha B Patel, Julia Pimkina, Johnathan Rine, Krista M Rubin, Maxwell Sauder, Sheila Shaigany, Afreen Shariff, Ryan J Sullivan, Leyre Zubiri, Kerry L Reynolds, Nicole R LeBoeuf
With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest, often with important downstream consequences for the patient. Current guidelines lack clarity in terms of diagnostic criteria for D-irAEs. The goal of this project is to better define D-irAE for the purposes of identification, diagnosis, and future study of this important group of diseases...
April 10, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38584198/hematological-indices-in-psoriatic-enthesopathy-relation-to-clinical-and-ultrasound-evaluation
#4
JOURNAL ARTICLE
Arwa S Amer, Ahmed Y Al Shambaky, Seham G Ameen, Amira Khalil Sobih
BACKGROUND: Enthesopathy is considered a crucial aspect of assessment and outcome in psoriatic arthritis (PsA). Musculoskeletal ultrasound (MSUS) is a critical tool for accurately detecting enthesitis. Recent research focuses on identifying simple biomarkers for detecting and monitoring psoriatic enthesopathy. Red cell distribution width (RDW), mean platelet volume (MPV), and neutrophil/lymphocyte ratio (NLR) are components of a complete blood count (CBC) and are reliable bio-inflammatory markers in various rheumatic diseases...
April 8, 2024: Clinical Rheumatology
https://read.qxmd.com/read/38457949/reasons-for-multiple-biologic-and-targeted-synthetic-dmard-switching-and-characteristics-of-treatment-refractory-rheumatoid-arthritis
#5
JOURNAL ARTICLE
Gregory C McDermott, Michael DiIorio, Yumeko Kawano, Mary Jeffway, Megan MacVicar, Kumar Dahal, Su-Jin Moon, Thany Seyok, Jonathan Coblyn, Elena Massarotti, Michael E Weinblatt, Dana Weisenfeld, Katherine P Liao
OBJECTIVE: Switching biologic and targeted synthetic DMARD (b/tsDMARD) medications occurs commonly in RA patients, however data are limited on the reasons for these changes. The objective of the study was to identify and categorize reasons for b/tsDMARD switching and investigate characteristics associated with treatment refractory RA. METHODS: In a multi-hospital RA electronic health record (EHR) cohort, we identified RA patients prescribed ≥1 b/tsDMARD between 2001 and 2017...
March 1, 2024: Seminars in Arthritis and Rheumatism
https://read.qxmd.com/read/38446584/mir-26a-5p-inhibits-the-proliferation-of-psoriasis-like-keratinocytes-in-vitro-and-in-vivo-by-dual-interference-with-the-cdc6-ccne1-axis
#6
JOURNAL ARTICLE
Jianing Li, Daxin Pang, Lin Zhou, Hongsheng Ouyang, Yaping Tian, Hao Yu
Psoriasis is a chronic inflammatory proliferative dermatological ailment that currently lacks a definitive cure. Employing data mining techniques, this study identified a collection of substantially downregulated miRNAs (top 10). Notably, 32 targets were implicated in both the activation of the IL-17 signaling pathway and cell cycle dysregulation. In silico analysis revealed that one of these miRNAs, miR-26a-5p, is a highly conserved cross-species miRNA. Strikingly, the miR-26a-5p sequences in humans and mice are identical, and mmu-miR-26a-5p was found to target the same 7 cell cycle targets as its human counterpart, hsa-miR-26a-5p...
March 5, 2024: Aging
https://read.qxmd.com/read/38444107/tildrakizumab-the-value-of-a-personalized-and-flexible-approach-for-treating-moderate-to-severe-plaque-psoriasis-in-patients-with-high-body-weight-or-high-disease-burden
#7
REVIEW
Paolo Dapavo, Martina Burlando, Claudio Guarneri, Matteo Megna, Alessandra Narcisi, Marina Talamonti, Paolo Gisondi
INTRODUCTION: The introduction of biologics for the treatment of plaque psoriasis is one of the major therapeutic advances of the last decades in dermatology. The efficacy of this class of drugs can be influenced by multiple factors including obesity, being overweight, prior treatment failures, and disease severity. AREAS COVERED: Most of the currently available approved biologics are limited by their lack of dosing flexibility for adapting the therapy to the complexity of real-world patients with psoriasis...
March 5, 2024: Expert Opinion on Biological Therapy
https://read.qxmd.com/read/38443645/satisfaction-with-the-injection-experience-of-a-new-citrate-free-formulation-of-ixekizumab
#8
JOURNAL ARTICLE
Sanjay Chabra, Julie Birt, Rebecca Bolce, Jeffrey Lisse, William N Malatestinic, Baojin Zhu, Miriam Kimel, Julie McCormack, Marissa Stefan, W Chad Cragun
INTRODUCTION: A new, citrate-free ixekizumab formulation, which is bioequivalent to the original formulation, was associated with significant reduction in injection site pain. This study evaluates patient satisfaction with the first injection experience of citrate-free ixekizumab in a real-world setting. METHODS: A non-interventional, observational, web-based survey of adults (≥ 18 years) with psoriasis, psoriatic arthritis, or axial spondyloarthritis was conducted between August 2022 and March 2023...
March 5, 2024: Advances in Therapy
https://read.qxmd.com/read/38439722/he-influence-of-academician-franjo-kogoj-on-global-dermatology
#9
REVIEW
Tomislav Duvančić, Mirna Šitum
Academician Franjo Kogoj graduated medicine in 1920 in Prague, where he then pursued training in dermatovenerology. During later years, he also visited other dermatology clinics in Europe, where he collaborated with renowned dermatologists of the time, such as in Breslau (present day Wroclaw in Poland) with Josef Jadassohn and in Strasbourg with Lucien-Marie Pautrier. He was also active in the famous Saint-Louis hospital in Paris. Academician Kogoj's scientific interests were especially focused on allergies, exanthemas, skin tuberculosis, and keratodermas...
December 2023: Acta Dermatovenerologica Croatica: ADC
https://read.qxmd.com/read/38433076/psoriasis-dermatitis-a-common-phenotype-of-early-forms-of-both-psoriasis-and-atopic-dermatitis-in-children-a-prospective-multicenter-study
#10
JOURNAL ARTICLE
Alexandre Docampo-Simón, Isabel Belinchón, María J Sánchez-Pujol, Laura Berbegal, Julia Miralles, Ana Lucas, Esther Quecedo, Amparo Fuertes, Almudena Mateu-Puchades, Isabel Betlloch
BACKGROUND: Psoriasis (Ps) and atopic dermatitis (AD) are chronic systemic immune-mediated diseases that can coexist in an overlapping condition called psoriasis dermatitis (PD). PD patients have intermediate lesions with characteristics of both Ps and AD. PD is very rare in adults but much more frequent in children. Little is known, however, about the course of PD in the pediatric population. The aim of this study was to evaluate the percentage of PD cases in children that evolved to a definite form of Ps or AD and to identify any clinical or epidemiological variables that could predict the course of the disease...
March 3, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38419411/defining-disease-severity-in-atopic-dermatitis-and-psoriasis-for-the-application-to-biomarker-research-an-inter-disciplinary-perspective
#11
JOURNAL ARTICLE
Ravi Ramessur, Nick Dand, Sinéad M Langan, Jake Saklatvala, Marie-Christine Fritzsche, Suzi Holland, Bernd W M Arents, Helen McAteer, Andrew Proctor, David McMahon, Michelle Greenwood, Alena M Buyx, Tamara Messer, Nina Weiler, Alexandra Hicks, Peter Hecht, Stephan Weidinger, Matladi N Ndlovu, Dai Chengliang, Matthias Hübenthal, Alexander Egeberg, Lavinia Paternoster, Lone Skov, Elke M G J De Jong, Maritza A Middelkamp-Hup, Satveer K Mahil, Jonathan N Barker, Carsten Flohr, Sara J Brown, Catherine H Smith
More severe atopic dermatitis (AD) and psoriasis are associated with a higher cumulative impact on quality of life, multimorbidity and healthcare costs. Proactive, early intervention in those most at risk of severe disease may reduce this cumulative burden and modify the disease trajectory to limit progression. The lack of reliable biomarkers for this at-risk group represents a barrier to such a paradigm shift in practice. To expedite discovery and validation, the BIOMAP consortium (Biomarkers in AD and Psoriasis, a large-scale European, inter-disciplinary research initiative) has curated clinical and molecular data across diverse study designs and sources including cross-sectional and cohort studies (small scale through to large multi-centre registries), clinical trials, electronic health records and large-scale population-based biobanks...
February 29, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38406185/causality-of-unsaturated-fatty-acids-and-psoriasis-a-mendelian-randomization-study
#12
JOURNAL ARTICLE
Junchen Li, Qian Shen, Chenqi Guo, Yingdong Wang, Yuxiao Ma, Yu Zhang
BACKGROUND: Many observational studies have identified a link between unsaturated fatty acids and psoriasis. However, they contain reverse causality and confounding factors, and there is no definite causal study between unsaturated fatty acids and psoriasis. OBJECTIVES: Analysis of causality between unsaturated fatty acids and psoriasis by Mendelian randomization. METHODS: We used IEU Open GWAS Project, omega-3 PUFA and omega-6 PUFA data from 114,999 subjects, MUFA data from 13,535 subjects, and psoriasis data from 4,510 cases and 212,242 controls were included...
2024: Frontiers in Nutrition
https://read.qxmd.com/read/38371137/the-management-of-plaque-psoriasis-with-halobetasol-and-tacrolimus-combination-therapy-versus-calcipotriol-monotherapy-a-case-report
#13
Mohammed Z Sarwar, Nawaid H Khan, MIrza Masroor Ali Beg, Niloufer Mariam Javeed Ankolvi, Kudaibergen Osmonaliev
Psoriasis is an inflammatory, immune-mediated, persistent, and multifactorial skin disease. Chronic plaque psoriasis is the most common clinical form of psoriasis. Pro-inflammatory cytokines play a primary role in the pathogenicity of this disease. Psoriasis is mainly diagnosed using clinical and dermoscopic examination of the cutaneous lesions, and skin biopsy is used in atypical cases. Psoriasis has no definitive cure. However, several topical agents are effective in managing mild and chronic cases. Combination therapy with these topical agents is more effective than with a single agent...
January 2024: Curēus
https://read.qxmd.com/read/38360611/the-effect-of-oenothera-biennis-evening-primrose-oil-on-inflammatory-diseases-a-systematic-review-of-clinical-trials
#14
JOURNAL ARTICLE
Melika Sharifi, Nasim Nourani, Sarvin Sanaie, Sanaz Hamedeyazdan
BACKGROUND: Evening primrose oil (EPO), extracted from the seeds of Oenothera biennis, has gained attention for its therapeutic effects in various inflammatory conditions. METHOD: We performed a systematic search in multiple databases and defined the inclusion criteria based on the following PICOs: P: Patients with a form of inflammatory condition, I: EPO, C: Placebo or other therapeutic interventions, O: changes in inflammatory markers or patients' symptoms; S: randomized controlled trials...
February 15, 2024: BMC complementary medicine and therapies
https://read.qxmd.com/read/38345734/targeting-the-nlrp3-inflammasome-in-psoriasis
#15
REVIEW
Xiuhui Chen, Guoliang Deng, Kaifeng Chen, Yanhong Chen, Weijun Ye, Ping Sun
The NLRP3 inflammasome, a complex consisting of the nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing protein 3, has emerged as a critical mediator of pathological inflammation and a significant therapeutic target for various inflammatory diseases. Psoriasis, a chronic inflammatory skin condition without a definitive cure, has shown promising results in animal models through the inhibition of the NLRP3 inflammasome. This review aims to explore the development of the NLRP3 inflammasome in psoriasis and the molecular mechanisms responsible for its inhibition by natural products and small molecules currently being developed for psoriasis treatment...
February 12, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38251522/association-between-biological-immunotherapy-for-psoriasis-and-time-to-incident-inflammatory-arthritis-a-retrospective-cohort-study
#16
JOURNAL ARTICLE
Shikha Singla, Michael Putman, Jean Liew, Kenneth Gordon
BACKGROUND: Targeted biological immunotherapies have been highly effective in controlling skin disease in patients with psoriasis, but whether therapy delays progression to inflammatory arthritis is unclear. The aim of this study was to compare the time to incident inflammatory arthritis among patients newly receiving biological therapies for psoriasis. METHODS: In this retrospective cohort study, we obtained data on a national sample of patients in the USA from the electronic health records database of the US-based TriNetX network...
April 2023: Lancet Rheumatology
https://read.qxmd.com/read/38191215/difficult-to-treat-psoriatic-arthritis-d2t-psa-a-scoping-literature-review-informing-a-grappa-research-project
#17
REVIEW
Shikha Singla, Andre Ribeiro, Murat Torgutalp, Philip J Mease, Fabian Proft
BACKGROUND: Psoriatic arthritis (PsA) is a multifaceted condition with a broad spectrum of manifestations and a range of associated comorbidities. A notable segment of patients with PsA remains resistant to even advanced therapeutic interventions. This resistance stems from myriad causes, including inflammatory and non-inflammatory factors. OBJECTIVES: To collate and critically assess the various definitions and criteria of difficult-to-treat (D2T PsA present in the literature...
January 8, 2024: RMD Open
https://read.qxmd.com/read/38168847/dose-reduction-is-a-feasible-strategy-in-patients-with-plaque-psoriasis-who-achieve-sustained-response-with-secukinumab-a-retrospective-multicenter-cohort-study-in-daily-practice-setting
#18
JOURNAL ARTICLE
Esteban Daudén, Elena Escario, Luisa Martos-Cabrera, Susana Armesto, Enrique Herrera-Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera, Pablo de la Cueva, Antonio Martorell, Ferran Ballesca, Isabel Belinchón, Gregorio Carretero, Lourdes Rodríguez, Alberto Romero-Maté, J Pujol-Montcusí, Laura Salgado, Antonio Sahuquillo-Torralba, Pablo Coto-Segura, Ofelia Baniandrés, R Feltes, Josep Riera-Monroig, Jesus Garrido, Mar Llamas-Velasco
BACKGROUND: Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. OBJECTIVE: The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications. METHODS: A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow-up...
January 2, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38160436/validation-of-claims-based-diagnoses-for-rheumatoid-arthritis-in-japan-results-from-the-validate-j-study
#19
JOURNAL ARTICLE
Naonobu Sugiyama, Mitsuyo Kinjo, Sadao Jinno, Cynthia de Luise, Toshitaka Morishima, Takakazu Higuchi, Kayoko Katayama, Haoqian Chen, Edward Nonnenmacher, Ryota Hase, Daisuke Suzuki, Yoshiya Tanaka, Soko Setoguchi
AIM: Validity of Algorithms in Large Databases: Infectious Diseases, Rheumatoid Arthritis, and Tumor Evaluation in Japan (VALIDATE-J) study examined algorithms for identifying rheumatoid arthritis (RA) in Japanese claims data. METHODS: VALIDATE-J was a multicenter, cross-sectional retrospective study. Disease-identifying algorithms were used to detect RA diagnosed between January 2012 and December 2016 using claims data from two Japanese hospitals. An RA diagnosis was confirmed using one of four gold standard definitions...
December 31, 2023: International Journal of Rheumatic Diseases
https://read.qxmd.com/read/38139369/a-multidisciplinary-approach-to-patients-with-psoriasis-and-a-history-of-malignancies-or-on-treatment-for-solid-tumors-a-narrative-literature-review
#20
REVIEW
Nerina Denaro, Gianluca Nazzaro, Giulia Murgia, Federica Scarfì, Carolina Cauchi, Carlo Giovanni Carrera, Angelo Cattaneo, Cinzia Solinas, Mario Scartozzi, Angelo Valerio Marzano, Ornella Garrone, Emanuela Passoni
Psoriasis is a chronic immune-mediated disease that is linked to an increased risk of cancer. Although numerous studies have explored whether neoplasms are concurrent conditions or are induced by psoriasis, a definitive definition remains elusive. In this study, we conducted a comprehensive narrative literature review to offer practical guidance to oncologists and dermatologists regarding the initiation and discontinuation of biologics for psoriasis. The findings indicate that a customized approach is recommended for each patient, and that a history of malignancies does not constitute an absolute contraindication for biologics...
December 16, 2023: International Journal of Molecular Sciences
keyword
keyword
110315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.